Sign in
WithdrawnPhase 2

A Trial of LY3056480 in Patients With SNLH

Key facts

Who runs it
Audion Therapeutics BV
Where
Chicago, New York, and Norfolk, United StatesSee the 3 sites
Trial code
Status
Withdrawn
Phase
Phase 2
Started
Sept 2022
Ended
Mar 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • LY3056480
Record updated
25 August 2022
Why it stopped
Study put on hold

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Male or female between 18 - 65 years of age
  • Minimum of six months of documented stable hearing loss (+/- 5dB)
  • A documented stable word recognition test (stable for ~ 6 months +/- 6%/3 words)

Who cannot take part

  • Any therapy known as ototoxic
  • Participant in a previous trial of LY3056480
  • History of suspected or diagnosed genetic cause of hearing loss
  • Suspected or known diagnosis of the following inner ear pathology, congenital hearing loss, fluctuating hearing loss, Ménière's disease, or secondary endolymphatic hydrops, perilymph fistula, cochlear barotrauma, autoimmune hearing loss, radiation-induced hearing loss, retro-cochlear lesion, ototoxicity
  • Evidence of acute or chronic otitis media or otitis externa on examination; or a history of middle ear pathology and/or surgery (except for ear tubes as a child)
  • Presenting with a primary complaint of tinnitus
  • Any conductive hearing loss of greater than 15 dB at a single frequency or greater than 10 dB at two or more contiguous octave frequencies in the study ear
  • Partial deafness as defined as hearing loss in any frequency (up to 8 kHz) greater than 80dB

Where in United States

  • Northwestern University Feinberg School of MedicineChicago, United States
  • New York Eye and Ear Infirmary ICAHN school of Medicine Mount SinaiNew York, United States
  • Eastern Virginia Medical SchoolNorfolk, United States

About the trial

What the trial wants to find out

A phase 2 trial with LY3056480 in patients with stable SNHL

The 2 groups in the trial

  • Four injections of 250µg LY3056480Treatment being tested

    The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below. * Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11 * Group 2 - Regimen 2. Weekly * Group 3 - Regimen 3. Every two weeks

    Treatment: LY3056480

  • Four injections of placeboPlacebo, for comparison

    The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below. * Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11 * Group 2 - Regimen 2. Weekly * Group 3 - Regimen 3. Every two weeks

    Treatment: LY3056480

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2 Double Blind, Randomized, Placebo Controlled Trial inVEstigating the Effect and Safety of Several Dosing Regimens of LY3056480 in Patients With STAble Sensorineural Hearing Loss
Record updated
25 August 2022